Adetola Kassim

(iStock image)
April 28, 2025

Three Vanderbilt-affiliated cellular therapy programs receive reaccreditation

The Vanderbilt and VA Tennessee Valley Healthcare System programs received notification after on-site inspections in October 2024. The accreditation is effective for three years.

By Tom Wilemon
(iStock)
February 27, 2025

VUMC part of new study validating curative therapy for sickle cell disease

Of 38 adults with severe SCD who participated in the study, more than 97% no longer required immunosuppressive therapy one year after the transplant.

By Bill Snyder
June 25, 2024

International trial introduces another curative option for sickle cell disease 

The therapy, haploidentical bone marrow transplant with thiotepa and posttransplant cyclophosphamide, is as safe and more affordable than the recently FDA-approved myeloablative gene therapy and gene editing treatments.

By Jessica Pasley
(iStock image)
April 24, 2024

VUMC hosts symposium on stem cell transplants and cellular therapies

The Vanderbilt Stem Cell Transplant and Cellular Therapy Symposium offers clinicians detailed information on the latest developments for hematological diseases, ranging from immunotherapies for blood cancers to new, curative therapies for sickle cell disease.

By Tom Wilemon